2025.07.04本文字数:3423,阅读时长大约8.6分钟导读:中国创新药产业近期迎来重大突破与拐点。百利天恒的全球首个EGFR×HER3双抗ADC在鼻咽癌III期临床成功,迪哲医药的舒沃哲获FDA批准,成中国首个独立研发在美获批的全球首创新药。同时,资本市场回暖,政策支持力度加大,为产业发展注入强劲动力。在短短48小时之内,中国创新药领域便接连抛出了两个“重磅炸弹”。一方面,百利天恒的全球...
Source Link2025.07.04本文字数:3423,阅读时长大约8.6分钟导读:中国创新药产业近期迎来重大突破与拐点。百利天恒的全球首个EGFR×HER3双抗ADC在鼻咽癌III期临床成功,迪哲医药的舒沃哲获FDA批准,成中国首个独立研发在美获批的全球首创新药。同时,资本市场回暖,政策支持力度加大,为产业发展注入强劲动力。在短短48小时之内,中国创新药领域便接连抛出了两个“重磅炸弹”。一方面,百利天恒的全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.